Cognito Therapeutics Presents Its Non-Invasive Device Therapy
References: businesswire
The medical technology firm Cognito Therapeutics has presented new research findings at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference concerning its experimental non-invasive device therapy for Alzheimer's disease. This innovation is dubbed Spectris™.
The presented data, which was derived from two separate studies, indicates that use of the device was associated with measurable biochemical changes in cerebrospinal fluid, specifically an increase in a protein linked to synaptic health and plasticity, alongside alterations in other proteins involved in neural protection. Additionally, electroencephalogram readings from a clinical trial suggested the non-invasive device therapy may slow the progression of certain brain wave patterns characteristic of the disease.
Christian Howell, CEO, Cognito Therapeutics, confirmed: “The data presented at CTAD strengthen the biological foundation behind Spectris™ and show that a non-invasive, at-home therapy can engage pathways central to brain resilience and health."
Image Credit: Cognito Therapeutics
The presented data, which was derived from two separate studies, indicates that use of the device was associated with measurable biochemical changes in cerebrospinal fluid, specifically an increase in a protein linked to synaptic health and plasticity, alongside alterations in other proteins involved in neural protection. Additionally, electroencephalogram readings from a clinical trial suggested the non-invasive device therapy may slow the progression of certain brain wave patterns characteristic of the disease.
Christian Howell, CEO, Cognito Therapeutics, confirmed: “The data presented at CTAD strengthen the biological foundation behind Spectris™ and show that a non-invasive, at-home therapy can engage pathways central to brain resilience and health."
Image Credit: Cognito Therapeutics
Trend Themes
1. Non-invasive Neuromodulation - Emerging non-invasive therapies offer innovative neuromodulation techniques that target neurological diseases like Alzheimer’s without the need for surgical intervention.
2. Home-based Health Devices - Portable and at-home health devices are transforming patient care by providing continuous treatment in a familiar and comfortable setting, making healthcare more accessible.
3. Biochemical Biomarker Monitoring - Advancements in monitoring biochemical markers in cerebrospinal fluid are enhancing our understanding of synaptic health and neural protection, paving the way for precision medicine.
Industry Implications
1. Medical Technology - The medical technology industry is witnessing a revolution with the development of devices that leverage non-invasive methods to treat chronic neurological conditions.
2. Home Healthcare - The home healthcare sector is evolving as new technologies enable patients to receive treatment in the comfort of their own homes, increasing convenience and compliance.
3. Biotech and Pharmaceuticals - Biotech and pharmaceutical companies are increasingly focusing on biomarker-driven strategies to develop targeted therapies that improve patient outcomes in neurological diseases.
7.1
Score
Popularity
Activity
Freshness
